Raghuraman Kannan,Ajit Prakash Zambre,Anandhi Upendran,Henry White
申请号：
US15525560
公开号：
US20200138971A1
申请日:
2015.11.13
申请国别(地区):
US
年份:
2020
代理人:
摘要：
A preferred embodiment is a method of formation of nanoparticle conjugates for cancer diagnostics, imaging and therapy, wherein the method allows determination a priori the efficacy of the nanoparticle conjugate for treatment of disease. A preferred stable pharmaceutical formulation includes a single antibody agent retaining its functionality in accordance with a predetermination of an a priori efficacy and electrostatically or covalently linked to a nanoparticle in a predetermined ratio in accordance with the a priori efficacy. Preferred embodiments also provide a method for forming single human antibody nanoparticle conjugates. The methods retain properties of the human antibody with a fabrication process that also allows control of the bonding mode of the antibody to the surface of AuNP, such that the bonding mode can be predetermined to be either electrostatic or covalent.
